UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

SEC File No: 000-53316

CUSIP No: 833592 108

(Check One):

☐     Form 10-K

☐     Form 20-F

☐     Form 11-K

☒     Form 10-Q

☐     Form 10-D

☐     Form N-SAR

☐     Form N-CSR

For Period Ended: June 30, 2020                

☐

Transition report on Form 10-K

☐

Transition report on Form 20-F

☐

Transition report on Form 11-K

☐

Transition report on Form 10-Q

☐

Transition report on Form N-SAR

For the Transition Period Ended: ___________

Read Instruction (on back page) Before Preparing Form Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

PART I -- REGISTRANT INFORMATION

SOBR Safe, Inc.

Full Name of Registrant

TransBiotec, Inc.

Former Name if Applicable

885 Arapahoe Road

Address of Principal Executive Office (Street and Number)

Boulder, Colorado 80302

City, State and Zip Code

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or a portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

(1)

David Gandini

(303)

443-4430

(Name)

(Area Code)

(Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes     ☐ No

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes     ☐ No

We anticipate our financial results for the three and six months ended June 30, 2020, will differ significantly from the prior year due to the fact we closed the transaction (the “Transaction”) that was the subject of that certain Asset Purchase Agreement dated May 6, 2019 (and Amendment No. 1 dated March 9, 2020, together the “APA”) with IDTEC, LLC (“IDTEC”), under which IDTEC agreed to provide personnel, experience, and access to funding to assist with the development of our SOBR device, as well as to sell to us certain robotics assets, which our management believes are synergistic with our current assets, in exchange for 12,000,000 shares of our common stock after giving effect to the reverse stock split effected in connection with closing the Transaction. As a result of the increase in our operations and the debt we assumed as a result of closing the Transaction, we expect our operating expenses, other expenses, and net loss will be significantly higher for the three and six months ended June 30, 2020, compared to the three and six months ended June 30, 2019. The exact amounts and the impact those amounts have on our financial statements will not be known until our financial statements for the three and six months ended June 30, 2020 are completed.

2

Date: August 14, 2020

By

/s/ David Gandini

David Gandini

Chief Financial Officer

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)

3